Literature DB >> 19789318

Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Kylie M Drake1, E Cristy Ruteshouser, Rachael Natrajan, Phyllis Harbor, Jenny Wegert, Manfred Gessler, Kathy Pritchard-Jones, Paul Grundy, Jeffrey Dome, Vicki Huff, Chris Jones, Micheala A Aldred.   

Abstract

PURPOSE: Wilms' tumor is a childhood cancer of the kidney with an incidence of approximately 1 in 10,000. Cooccurrence of Wilms' tumor with 2q37 deletion syndrome, an uncommon constitutional chromosome abnormality, has been reported previously in three children. Given these are independently rare clinical entities, we hypothesized that 2q37 harbors a tumor suppressor gene important in Wilms' tumor pathogenesis. EXPERIMENTAL
DESIGN: To test this, we performed loss of heterozygosity analysis in a panel of 226 sporadic Wilms' tumor samples and mutation analysis of candidate genes.
RESULTS: Loss of heterozygosity was present in at least 4% of cases. Two tumors harbored homozygous deletions at 2q37.1, supporting the presence of a tumor suppressor gene that follows a classic two-hit model. However, no other evidence of second mutations was found, suggesting that heterozygous deletion alone may be sufficient to promote tumorigenesis in concert with other genomic abnormalities. We show that miR-562, a microRNA within the candidate region, is expressed only in kidney and colon and regulates EYA1, a critical gene for renal development. miR-562 expression is reduced in Wilms' tumor and may contribute to tumorigenesis by deregulating EYA1. Two other candidate regions were localized at 2q37.3 and 2qter, but available data from patients with constitutional deletions suggest that these probably do not confer a high risk for Wilms' tumor.
CONCLUSIONS: Our data support the presence of a tumor suppressor gene at 2q37.1 and suggest that, in individuals with constitutional 2q37 deletions, any increased risk for developing Wilms' tumor likely correlates with deletions encompassing 2q37.1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789318      PMCID: PMC2756455          DOI: 10.1158/1078-0432.CCR-09-1065

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Molecular analysis of 20 patients with 2q37.3 monosomy: definition of minimum deletion intervals for key phenotypes.

Authors:  M A Aldred; R O C Sanford; N S Thomas; M A Barrow; L C Wilson; L A Brueton; M C Bonaglia; R C M Hennekam; C Eng; N R Dennis; R C Trembath
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

2.  A single subunit, Dis3, is essentially responsible for yeast exosome core activity.

Authors:  Andrzej Dziembowski; Esben Lorentzen; Elena Conti; Bertrand Séraphin
Journal:  Nat Struct Mol Biol       Date:  2006-12-17       Impact factor: 15.369

3.  Origin and evolution of human microRNAs from transposable elements.

Authors:  Jittima Piriyapongsa; Leonardo Mariño-Ramírez; I King Jordan
Journal:  Genetics       Date:  2007-04-15       Impact factor: 4.562

4.  Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays.

Authors:  Shahrad Rod Rassekh; Suzanne Chan; Chansonette Harvard; David Dix; Ying Qiao; Evica Rajcan-Separovic
Journal:  Cancer Genet Cytogenet       Date:  2008-04-15

5.  Wilms' tumor and gonadal dysgenesis in a child with the 2q37.1 deletion syndrome.

Authors:  G Viot-Szoboszlai; J Amiel; F Doz; M Prieur; J Couturier; J N Zucker; I Henry; A Munnich; M Vekemans; S Lyonnet
Journal:  Clin Genet       Date:  1998-04       Impact factor: 4.438

Review 6.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

7.  p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.

Authors:  Masayuki Shiseki; Makoto Nagashima; Remy M Pedeux; Mariko Kitahama-Shiseki; Koh Miura; Shu Okamura; Hitoshi Onogi; Yuichiro Higashimoto; Ettore Appella; Jun Yokota; Curtis C Harris
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

Review 8.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

9.  International variations in the incidence of childhood renal tumours.

Authors:  C A Stiller; D M Parkin
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

10.  Loss of heterozygosity at 7p in Wilms' tumour development.

Authors:  R M Powlesland; A K Charles; K T Malik; P A Reynolds; S Pires; M Boavida; K W Brown
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  25 in total

1.  Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.

Authors:  Dewi Astuti; Mark R Morris; Wendy N Cooper; Raymond H J Staals; Naomi C Wake; Graham A Fews; Harmeet Gill; Dean Gentle; Salwati Shuib; Christopher J Ricketts; Trevor Cole; Anthonie J van Essen; Richard A van Lingen; Giovanni Neri; John M Opitz; Patrick Rump; Irene Stolte-Dijkstra; Ferenc Müller; Ger J M Pruijn; Farida Latif; Eamonn R Maher
Journal:  Nat Genet       Date:  2012-02-05       Impact factor: 38.330

Review 2.  Genetic, environmental, and epigenetic factors involved in CAKUT.

Authors:  Nayia Nicolaou; Kirsten Y Renkema; Ernie M H F Bongers; Rachel H Giles; Nine V A M Knoers
Journal:  Nat Rev Nephrol       Date:  2015-08-18       Impact factor: 28.314

Review 3.  MicroRNAs: potential regulators of renal development genes that contribute to CAKUT.

Authors:  April K Marrone; Jacqueline Ho
Journal:  Pediatr Nephrol       Date:  2013-09-03       Impact factor: 3.714

Review 4.  microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles.

Authors:  Kirti Bhatt; Qing-Sheng Mi; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

Review 5.  The Eyes Absent proteins in development and disease.

Authors:  Emmanuel Tadjuidje; Rashmi S Hegde
Journal:  Cell Mol Life Sci       Date:  2012-09-13       Impact factor: 9.261

Review 6.  MicroRNAs and their applications in kidney diseases.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  Pediatr Nephrol       Date:  2014-06-14       Impact factor: 3.714

Review 7.  Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors.

Authors:  Annika Schaefer; Carsten Stephan; Jonas Busch; George M Yousef; Klaus Jung
Journal:  Nat Rev Urol       Date:  2010-04-06       Impact factor: 14.432

Review 8.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

9.  EYA1 expression in gastric carcinoma and its association with clinicopathological characteristics: a pilot study.

Authors:  Parvaneh Nikpour; Modjtaba Emadi-Baygi; Elaheh Emadi-Andani; Shima Rahmati
Journal:  Med Oncol       Date:  2014-04-12       Impact factor: 3.064

Review 10.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.